News

Vical is collaborating with the university’s School of Medicine and the Sealy Center for Vaccine Development under a previously disclosed grant on the preclinical development of an HSV-2

Boehringer Ingelheim will carry out the technical development, clinical manufacturing and all related regulatory filing support services for antibodies discovered by Elan. Elan will guide the discovery science,

POTELLIGENT CHOK1SV is a new host cell line for manufacturing recombinant antibodies. It combines the power of BioWa’s engineered glycosylation POTELLIGENT Technology with the advantages of Lonza’s proprietary

The trial is designed to evaluate multiple objective efficacy measures in order to support the design of the Phase 3 clinical studies. The randomised, double blind, Phase 2b

Elesclomol is a first-in-class investigational drug candidate that triggers programmed cell death in cancer cells by targeting mitochondrial energy production in cancer cells. The trial, which will enroll

The NON outlined Health Canada’s concerns, which are focused mainly on chemistry, manufacturing, and control (CMC) and preclinical toxicology issues. Health Canada has requested additional information on polyglucose

Annual non-GAAP net income and non-GAAP EPS was $4.1bn and $4.54, up 36% and 35%, respectively, compared to 2009. For the fourth quarter, non-GAAP net income and non-GAAP

The Redcar-based firm intends to use the funds to accelerate the development of a pioneering probe that monitors bio-processes using cells, or parts of them to make medicines

The Prelude SkinPrep System is a transdermal drug delivery system designed as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals Echo anticipates that the